Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 2Meningeal Carcinomatosis 1Glioma 1

Interventions

Temozolomide 43Magnetic Resonance Spectroscopy 39Specimen Handling 28Radiotherapy 19Radiation 16Bevacizumab 13Radiosurgery 12Nivolumab 12Biopsy 12X-Rays 10Cyclophosphamide 9Carboplatin 9Nuclear Medicine Department, Hospital 7Lomustine 7Irinotecan 7pembrolizumab 6Ipilimumab 6Cisplatin 6AZD 6244 6Vincristine 5Topotecan 5Phantoms, Imaging 5Etoposide 5CTLA-4 Antigen 5ulixertinib 4trametinib 4olaparib 4erdafitinib 4dinutuximab 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
azeliragon × CNS × 30 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡